NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00382031,Zalutumumab in Patients With Non-curable Head and Neck Cancer,https://clinicaltrials.gov/study/NCT00382031,,COMPLETED,The purpose of this study is to investigate if zalutumumab in combination with Best Supportive Care (BSC) is superior to BSC in non-curable patients with head and neck cancer,YES,Head and Neck Cancer|Squamous Cell Cancer,DRUG: Zalutumumab|OTHER: Control,"Overall Survival, A patient's overall survival was defined as the time from the date of randomization until the date of death from any cause, assessed up to 41 months. Overall survival was censored if the patient was lost to follow-up or refused to continue in the trial., From randomization until death","Objective Tumor Response, Objective tumor response assessed according to Response Evaluation Criteria in Solid Tumours (RECIST v 1.0) J Natl Cancer Inst 2000;92:205-16 assessed by CT/MRI. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the longest diameter of target lesions; Overall Response (OR), CR+PR, From date of randomization until the date of death from any cause, assessed up to 41 months.|Duration of Response, Duration of response defined as the time from the first date where measurement criteria for complete or partial response (whichever status is recorded first) are met until the first date that death, recurrence or progressive disease is objectively documented., Time from complete or partial response until death, recurrence or progressive disease, assessed up to 41 months.|Progression Free Survival (PFS), PFS (defined as the time from randomization until disease progression or death). The progression events were defined by well-documented and verifiable imaging data. In case of censoring, the date of censoring had to be the last time point documenting the status of the patient., From randomization until disease progression or death, assessed up to 41 months.",,Genmab,,ALL,"ADULT, OLDER_ADULT",PHASE3,286,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,Hx-EGFr-202,2006-11,2009-12,2011-08,2006-09-28,2013-10-15,2013-10-15,"University Hospital Antwerp, Antwerp, Belgium|St-Luc University Hospital, Brussels, Belgium|CHNDRF, Charleroi, Belgium|""University Hospital, Gent, Belgium|University Hospital Leuven, Leuven, Belgium|Cliniques Saint Pierre, Ottignies, Belgium|BioCancer, Belo Horizonte, Brazil|Hospital Erasto Gaertner, Curitiba, Brazil|Centro Goiano de Oncologia, Goiânia, Brazil|Hospital Araújo Jorge, Goiânia, Brazil|Fundação Amaral Carvalho, Jaú, Brazil|CliniOnco, Porto Alegre, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|Cepho - Centro de Estudos e pesquisa em Hematologia e Oncologia, Santo André, Brazil|Santo Andre Diag e Tratamentos, Santo André, Brazil|UNIFESP, São Paulo - SP, Brazil|Centro de Oncologia - InRad HCFMUSP, São Paulo, Brazil|Hospital Heliópolis, São Paulo, Brazil|IBCC - Instituto Brasileiro de Combate ao Câncer, São Paulo, Brazil|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|London Regional Cancer Program, London, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|BC Cancer Agency, Vancouver, British Colombia, Canada|North-Estonian Regional Hospital, Tallinn, Estonia|Hôpital Beaujon- department of medical oncology, Clichy, France|Centre Oscar Lambrette, Lille Cedex, France|Centre Antoine Lacassagne, Nice, France|Hôpital Tenon - department of medical oncology, Paris Cedex, France|Institut Gustave Roussy, Villejuif Cedex, France|Semmelweis University, Budapest, Hungary|Uzsoki Hospital Budapest, Budapest, Hungary|University of Debrecen, Debrecen, Hungary|Petz Aladár, Gyor, Hungary|Szabolcs-Szatmar-Bereg County Hospital, Nyiregyhaza, Hungary|University of Szeged, Szeged, Hungary|Markusovszky County Hospital, Szombathely, Hungary|Szent Borbála County Hospital Oncology Department, Tatabánya, Hungary|Zala County Hospital, Zalaegerszeg-Pózca, Hungary|Klaipeda Hospital, Klaipeda, Lithuania|Vilnius University, Vilnius, Lithuania|Beskidzkie Centrum Onkologii, Bielsko-Biala, Poland|Samodzielny Publiczny Szpital Kiniczny Nr1, Gdansk, Poland|Katedra i Onkologii Collegium, Krakow, Poland|Szpital Specjalistyczny im. Rydygiera, Krakow, Poland|Centrum Onkologii, Lublin, Poland|Zakład Opieki Zdrowotnej MSWiA z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie, Olsztyn, Poland|Centrum Onkologii - Instytut im. M. Curie-Skłodowskiej, Warszawa, Poland|Dolnoslaskie Centrum Onkologii, Wroclaw, Poland|Szpital Wojewódzki SP ZOZ, Zielona Góra, Poland|Belgorod Regional Oncology Dispensary, Belgorod, Russian Federation|Regional Oncology Dispensary, Chelyabinsk, Russian Federation|Republican Clinical Oncology Dispensary, Izhevsk, Russian Federation|Kursk Regional Oncology Dispencary, Kursk, Russian Federation|Kursk Regional Oncology Dispensary, Kursk, Russian Federation|City Clinincal Oncology Dispensary #1, Moscow, Russian Federation|Moscow Research Institute of Oncology, Moscow, Russian Federation|NUZ Semashko Central Clinical Hospital No2 OAO, Moscow, Russian Federation|Russian Oncology Research Center n.a. Blokhin, Moscow, Russian Federation|GUZ NO Oncology Dispensary, Nizhiy Novgorod, Russian Federation|Medical Radiological Research Center, Obninsk, Russian Federation|Sochi Oncology Center, Sochi, Russian Federation|St. Petersburg State Medical University, St. Petersburg, Russian Federation|Stavropol Regional Clinical Oncology Dispensary, Stavropol, Russian Federation|Tula Region Oncology Dispensary, Tula, Russian Federation|GUZ Volgograd Region Clinical Oncology Dispensary No1, Volgograd, Russian Federation|Voronezh Region Clinical Oncology Dispensary, Voronezh, Russian Federation|Institute for Oncology and Radiology, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|Institute of Oncology Sremska Kamenica, Kamenica, Serbia|Clinic of Maxillofacial Surgery Nis, Nis, Serbia|Sahlgrenska University Hospital, Göteborg, Sweden|Lund University Hospital, Lund, Sweden|Musgrove Park Hospital, Taunton, Somerset, United Kingdom|Royal Surrey County, Guildford, Surrey, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|The Beatson West of Scotland Centre, Glasgow, United Kingdom|Royal Marsden Hospital, London, United Kingdom|Christie Hospital, Manchester, United Kingdom|Newcastle General Hospital, Newcastle, United Kingdom|Weston Park Hospital, Sheffield, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom",
